Research Vision:

We have been developing a series of cancer-targeted oncolytic adenovirus using Adenovirus-based library screening system. Our goal is to develop an oncolytic adenovirus enabling treatment of patients with advanced or spread diseases by systemic injection.

Research Areas:

• Oncolytic adenovirus therapy

• Adenovirus-based library screening system

• Pancreatic cancer, colon cancer

Research Publications:

1. Sato-Dahlman M, Miura Y, Huang JL, Hajeri P, Jacobsen K, Davydova J, Yamamoto M. CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer. Oncotarget. (2017) Jun 2;8(44):76044-76056, PMID: 29100290

2. Yoshida H, Sato-Dahlman M, Hajeri P, Jacobsen K, Koodie L, Yanagiba C, Shanley R, Yamamoto M. Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells. Transl Oncol. (2021) Feb;14(2):100997. doi: 10.1016/j.tranon.2020.100997, PMID: 33037318

3. Sato-Dahlman M, Wirth K, Yamamoto M. Role of Gene Therapy in Pancreatic Cancer-A Review. Cancers (Basel). (2018) Apr; 10(4): 103. PMID: 29614005

4. Sato-Dahlman M, LaRocca C, Yanagiba C, Yamamoto M. Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination. Cancers (Basel). 2020 May 21;12(5):1295. PMID: 32455560

5. LaRocca C, Salzwedel A, Sato-Dahlman M, Romanenko M, Andrade R, Davydova J, & Yamamoto M. Interferon Alpha-Expressing Oncolytic Adenovirus for Treatment of Esophageal Adenocarcinoma. Ann Surg Oncol (2021) Jul 29. PMID: 34324109